

**ONGENTYS (opicapone, oral)**

**Diagnosis Considered for Coverage:**

- Parkinson's disease (PD)

**Coverage Criteria:**

**For diagnosis listed above:**

- Being used to treat PD "off" episodes, and
- Inadequate response, intolerable side effect, or contraindication to entacapone (Comtan), and
- Dose does not exceed FDA label maximum.

**Coverage Duration:** one year

Effective Date: 11/30/2022